Back to GetFilings.com



Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 10-Q

 


 

(Mark one)

x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the quarterly period ended September 30, 2004

 

OR

 

¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Commission File Number: 0-27696

 


 

GENSYM CORPORATION

(Exact name of registrant as specified in its charter)

 


 

Delaware   04-2932756

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

52 Second Avenue

Burlington, MA 01803

(Address of principal executive offices)

 

Telephone Number (781) 265-7100

(Registrant’s telephone number, including area code)

 


 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:    Yes  x    No  ¨

 

Indicate by checkmark whether the registrant is an accelerated filer (as defined in Rule 12-b-2 of the Exchange Act)    Yes  ¨    No  x

 

As of November 15, 2004 there were 7,255,377 shares of the Registrant’s Common Stock outstanding.

 



Table of Contents

GENSYM CORPORATION

 

INDEX

 

Part I— Financial Information

Item 1.   Consolidated Financial Statements (Unaudited)     
    Consolidated Balance Sheets as of September 30, 2004 and December 31, 2003 (Unaudited)    3
    Consolidated Statements of Operations for the Three - and Nine-Months Ended September 30, 2004 and 2003 (Unaudited)    4
    Consolidated Statements of Cash Flows for the Nine-Months Ended September 30, 2004 and 2003 (Unaudited)    5
    Notes to Consolidated Financial Statements    6
Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations    11
Item 3.   Qualitative and Quantitative Disclosures About Market Risk    21
Item 4.   Controls and Procedures    21
Part II— Other Information
Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds    24
Item 6.   Exhibits    25
    Signatures    26
    Exhibit Index    27

 

2


Table of Contents

PART I. FINANCIAL INFORMATION

 

ITEM 1. Consolidated Financial Statements

 

GENSYM CORPORATION

CONSOLIDATED BALANCE SHEETS

(Unaudited)

(in thousands, except share amounts)

 

     September 30,
2004


    December 31,
2003


 

ASSETS

                

Current Assets:

                

Cash and cash equivalents

   $ 2,969     $ 1,818  

Accounts receivable, net

     2,733       4,015  

Prepaid and other current assets

     585       872  
    


 


Total current assets

     6,287       6,705  

Property and equipment, net

     582       908  

Deposits and other assets

     528       673  
    


 


Total Assets

   $ 7,397     $ 8,286  
    


 


LIABILITIES AND STOCKHOLDERS’ EQUITY

                

Current Liabilities:

                

Accounts payable

     666       235  

Accrued expenses

     1,671       2,134  

Current portion of capital lease obligations

     40       83  

Deferred revenue

     3,704       4,991  
    


 


Total current liabilities

     6,081       7,443  

Other long-term liabilities

     10       41  

Long-term deferred revenue

     94       150  
    


 


Total liabilities

     6,185       7,634  
    


 


Stockholders’ Equity:

                

Preferred stock, $.01 par value—Authorized—2,000,000 shares; issued and outstanding - none

     —         —    

Common stock, $.01 par value—Authorized—20,000,000 shares; issued—7,599,962 shares in 2004 and 7,501,105 shares in 2003

                

Outstanding—7,231,643 shares in 2004 and 7,111,893 in 2003

     76       75  

Capital in excess of par value

     21,955       21,889  

Treasury stock—368,319 shares in 2004 and 389,212 shares in 2003, at cost

     (1,373 )     (1,458 )

Accumulated deficit

     (19,741 )     (20,086 )

Accumulated other comprehensive income

     293       232  
    


 


Total stockholders’ equity

     1,212       652  
    


 


Total liabilities and stockholders’ equity

   $ 7,397     $ 8,286  
    


 


 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

3


Table of Contents

GENSYM CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(in thousands, except per share amounts)

 

     Three months ended
September 30,


    Nine months ended
September 30,


 
     2004

    2003

    2004

    2003

 

Revenues:

                                

Product

   $ 1,607     $ 1,267     $ 5,376     $ 3,269  

Services

     2,822       2,603       7,509       7,409  
    


 


 


 


Total revenues

     4,429       3,870       12,884       10,678  

Cost of revenues:

                                

Product

     109       248       588       579  

Services

     1,319       884       3,049       2,276  
    


 


 


 


Total cost of revenues

     1,428       1,132       3,637       2,855  
    


 


 


 


Gross profit

     3,001       2,738       9,247       7,823  

Operating expenses:

                                

Sales and marketing

     1,077       1,200       3,225       4,315  

Research and development

     822       869       2,568       2,547  

General and administrative

     969       1,214       2,906       3,010  

Restructuring charge

     —         —         —         250  
    


 


 


 


Total operating expenses

     2,868       3,283       8,699       10,122  

Operating income (loss)

     133       (545 )     548       (2,299 )

Other income (expense), net

     (110 )     220       (175 )     329  
    


 


 


 


Income (loss) before provision for income taxes

     23       (325 )     373       (1,970 )

Provision (benefit) for income taxes

     (68 )     16       (24 )     195  

Net income (loss)

   $ 91     $ (341 )   $ 397     $ (2,165 )
    


 


 


 


Basic earnings (loss) per share

   $ 0.01     $ (0.05 )   $ 0.06     $ (0.31 )

Diluted earnings (loss) per share

   $ 0.01     $ (0.05 )   $ 0.05     $ (0.31 )

Basic weighted average common shares outstanding

     7,225       7,012       7,175       6,931  

Diluted weighted average common shares outstanding

     8,033       7,012       7,896       6,931  

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

4


Table of Contents

GENSYM CORPORATION

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)

 

     Nine months ended
September 30,


 
     2004

    2003

 

CASH FLOWS FROM OPERATING ACTIVITIES:

                

Net income (loss)

   $ 397     $ (2,165 )

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

                

Depreciation and amortization

     413       548  

Loss on disposal of equipment

     6       30  

Non-cash compensation

     35       45  

Provision for bad debt

     (93 )     9  

Changes in assets and liabilities:

                

Accounts receivable

     1,371       1,004  

Prepaid expenses and other assets

     (121 )     (150 )

Accounts payable

     431       68  

Accrued expenses

     (457 )     (262 )

Decrease in deposits and other assets

     471       —    

Restructuring

     —         211  

Deferred revenue

     (1,340 )     (872 )
    


 


Net cash provided by (used in) operating activities

     1,113       (1,534 )
    


 


CASH FLOWS FROM INVESTING ACTIVITIES:

                

Purchases of property and equipment

     (32 )     (309 )

Purchase of intangible assets

     —         (250 )
    


 


Net cash used in investing activities

     (32 )     (559 )
    


 


CASH FLOWS FROM FINANCING ACTIVITIES:

                

Borrowing under capital lease arrangements

             102  

Payments on capital lease obligations

     (73 )     (113 )

Proceeds from exercise of stock options and issuance of common stock under stock plans

     66       56  
    


 


Net cash provided by (used in ) financing activities

     (7 )     19  
    


 


EFFECT OF EXCHANGE RATE CHANGES ON CASH

     77       143  
    


 


NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

     1,151       (1,911 )

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD

     1,818       3,884  
    


 


CASH AND CASH EQUIVALENTS, END OF PERIOD

   $ 2,969     $ 1,973  

SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES

                

Acquisition of equipment under capital lease obligations

   $ —       $ 54  

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

5


Table of Contents

GENSYM CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

1. Operations

 

We are a provider of operations management and expert systems software products and services. Our products emulate the reasoning of human experts, using process knowledge and often real-time data, and then, on the basis of such reasoning, make recommendations or take direct operational actions. Most applications of our products are in the areas of abnormal condition and process performance management in manufacturing, supply chain and logistics management, and network management. Benefits derived from the use of our products include waste reduction, avoidance of off-specification product, avoidance of system downtime in mission-critical networks, and proactive alarms that signify potential process problems and avoid plant shutdowns. Our products have been used in the manufacturing, transportation, communications, aerospace and government sectors for many years.

 

2. Basis of Presentation

 

We have prepared the unaudited consolidated financial statements included in this report pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. Certain information and footnote disclosures, normally included in financial statements prepared for the full year in accordance with accounting principles generally accepted in the United States of America, have been condensed or omitted pursuant to such SEC rules and regulations; nevertheless, our management believes that the disclosures in this report are adequate to make the information presented not misleading. In the opinion of management, the consolidated financial statements reflect all adjustments (of a normal and recurring nature) that are necessary to present fairly our consolidated financial position as of September 30, 2004 and our results of operations and cash flows for the three- and nine- month periods ended September 30, 2004 and 2003. These consolidated financial statements and notes thereto should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2003, filed with the SEC on March 30, 2004. The results of operations for interim periods are not necessarily indicative of the results of operations for the full year or any other interim period. Certain prior period amounts have been reclassified to conform to the current period presentation.

 

During the year ended December 31, 2003, we sustained a significant loss in the first half of the year. Based on these results, management affected a restructuring plan designed to return the Company to profitability by year’s end without sacrificing our significant engineering investments in a next generation of products. Previously, we had achieved operating and overall profitability as well as positive cash flows for the year ended December 31, 2002. We believe that our cash and cash equivalents and cash flows from operations will be sufficient to meet our operating, investing and financing cash flow requirements through at least the next 12 months. Our ability to maintain growth and profitability in 2004 and beyond is dependent on market acceptance of our existing and next generation of G2 and G2-based products and related services and on renewal of maintenance contracts for customer support at near-current levels.

 

Our financial statements have been prepared under the assumption that we will continue as a going concern. Based on current forecasts, management believes that we have sufficient liquidity to finance operations for the next twelve months. Management’s expectations for future revenue growth, profitability, and operating cash flows involve significant judgments and estimates. Should these judgments and estimates prove to be inaccurate, we have the intent and ability to reduce our costs and delay, scale back, or eliminate certain of our activities in order to ensure that we maintain positive cash and working capital. Any of these actions could have a material adverse long-term effect on our business, financial condition and results of operations.

 

6


Table of Contents

GENSYM CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

 

3. Comprehensive Income (Loss )

 

The components of comprehensive income (loss) for the three- and nine-month periods ended September 30, 2004 and 2003 are as follows (in thousands):

 

     Three months ended
September 30,


    Nine months ended
September 30,